drugset / Trial / NCT04040491
PD-1 Antibody, Chidamide, Lenalidomide and Gemcitabine for Peripheral T-cell Lymphoma
Parallel-groupOpen-labelTreatment
Summary
To observe the safety, tolerability and clinical effects of PD-1, chidamide, lenalidomide and gemcitabine in the treatment of newly diagnosed and relapse/refractory peripheral T-cell lymphoma.
Timeline
- Start
- 2019-09-01
- Primary completion
- 2020-12-01
- Completion
- 2021-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gemcitabine | Small molecule | 600 mg/m2 | — |
| Subject | Lenalidomide | Other / unclassified | 10 mg | — |
| Subject | Tucidinostat | Small molecule | 30 mg | — |